CLCM
IOVA icon

Crawford Lake Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Crawford Lake Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-272,841
Closed -$7.55M – 51
2019
Q4 		$7.55M Buy
+272,841
New +$6.21M 1.15% 27

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Crawford Lake Capital Management's IOVA Position: Q1 2020 in Review

Crawford Lake Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2020, closing a stake of 272,841 shares — an estimated $7.55M sold.

Crawford Lake Capital Management first reported a position in IOVA in Q4 2019 and held it in 1 quarter. The position peaked at $7.55M in Q4 2019. 219 funds tracked by Wall St. Rank hold IOVA as of Q1 2020.

  • Crawford Lake Capital Management reported no remaining Iovance Biotherapeutics position as of Q1 2020 after selling out during the quarter.
  • Crawford Lake Capital Management sold 272,841 Iovance Biotherapeutics shares in Q1 2020, an estimated $7.55M.
  • Crawford Lake Capital Management first reported a position in Iovance Biotherapeutics in Q4 2019 and held it in 1 quarter.
  • Crawford Lake Capital Management's Iovance Biotherapeutics position peaked at $7.55M in Q4 2019.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2020.

Based on Crawford Lake Capital Management's 13F filing for Q1 2020, filed 15 May 2020.